Ordinary competitors, the Pfizer, BioNTech, and Sanofi laboratories will work for hand in hand to package more than 100 million doses intended for the European Union by the end of 2021. The announcement was made Tuesday in the columns of the Figaro by Paul Hudson, CEO of Sanofi. The French laboratory is itself working on two vaccines to fight this pandemic, but its main project is behind schedule and should not hit the market before the end of the year. In the meantime, the French government had urged it on several occasions in recent weeks to study the possibility of making its production lines available to increase the production of already existing vaccines.
Announcing that he had signed an agreement on Tuesday, Mr. Hudson explains in the interview published on the website of the Figaro that Sanofi will use its German factory in Frankfurt to bottle the vaccine that will be supplied to it by its competitors from July. “This production site being located near the headquarters of BioNTech (in Mainz, Editor’s note), this will make things easier”, argues the boss of the French group. The production will be destined for the European Union and therefore partly for France, he added.
Criticized delays
Laboratories have to cope with high speeds to meet demand and some, including Pfizer and BioNTech, have had to face delays. On Tuesday, the President of the European Commission, Ursula von der Leyen, put further pressure on manufacturers by saying that they must “honor their obligations”. “Europe has invested billions to develop the first vaccines and create a real global common good. Now companies must keep their promises, ”she argued in a video intervention at the World Economic Forum in Davos.
Regarding his own projects, Paul Hudson ensures that the recombinant protein one, a technology that Sanofi uses for its influenza vaccine, “is progressing well”, despite a few months of delay, and should arrive on the market in the last quarter of 2021. The laboratory is also developing a vaccine based on messenger RNA technology, used in particular by Pfizer and BioNTech, in partnership with American biotech. “We think we can enter the clinical phase with an RNA vaccine against Covid from the first quarter of this year”, hoped Paul Hudson.

Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.